Compared to Estimates, Guardant Health (GH) Q4 Earnings: A Look at Key Metrics

Core Insights - Guardant Health reported revenue of $281.27 million for Q4 2025, a year-over-year increase of 39.4% [1] - The EPS for the same period was -$0.50, an improvement from -$0.62 a year ago, but below the consensus estimate of -$0.42, resulting in an EPS surprise of -18.12% [1] - The revenue exceeded the Zacks Consensus Estimate of $279.96 million by 0.47% [1] Financial Performance Metrics - Total oncology tests performed were 79,000, surpassing the average estimate of 75,360 from three analysts [4] - Revenue from oncology tests was $189.95 million, compared to the average estimate of $186.77 million from four analysts [4] - Revenue from licensing and other sources was $2.18 million, exceeding the estimated $2 million [4] - Revenue from screening reached $35.13 million, significantly higher than the average estimate of $27.31 million [4] - Revenue from biopharma and data was $54.01 million, compared to the average estimate of $50.47 million [4] Stock Performance - Over the past month, shares of Guardant Health have returned -7.2%, while the Zacks S&P 500 composite changed by -0.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]